2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06G.19 Characterization of Metabolomic Landscape in Underrepresented Patients with Lung Cancer

Pdf Summary

The study aims to characterize the metabolomic landscape in patients with lung cancer, focusing on underrepresented populations. The investigation involved collecting plasma samples from 40 patients with confirmed lung cancer (both non-small cell and small cell) and 62 control patients without a diagnosis of lung cancer. The lung cancer samples were collected under the Lung Bio protocol, while the control samples followed the EDPR protocol.<br /><br />Metabolomic profiling utilized ultra-high-performance liquid chromatography-mass spectrometry. Data were analyzed using MetaboAnalyst 5.0, with subsequent orthogonal partial least squares discriminant analysis (OPLS-DA) to differentiate between the metabolite profiles of cancerous and non-cancerous samples. Metabolites were sorted according to their Variable Importance in Projection (VIP) scores to determine their significant differences and contributions.<br /><br />The analysis revealed noteworthy differences in metabolite expression between lung cancer and control samples. Notably, certain amino acids, including those involved in arginine synthesis such as cystine, were found to be decreased in lung cancer patients, which contrasts with their typically higher levels found in other cancer patients. The study underscores the relevance of metabolomic profiling in understanding the biochemical pathways and metabolic variations linked to lung cancer malignancies.<br /><br />Future directions include analyzing anthropometric factors contributing to metabolite expression differences and utilizing geospatial data to identify neighborhood-level variations in metabolite enrichment. This could pave the way for personalized therapy and improve understanding of demographic impacts on lung cancer behavior. The research highlights the potential for tailored treatment options in lung cancer by elucidating distinct metabolic pathways associated with various patient populations.

Asset Subtitle

Joshua Pothen

Meta Tag

Speaker Joshua Pothen

Topic Pathology and Biomarkers

Keywords

metabolomic landscape

lung cancer

underrepresented populations

ultra-high-performance liquid chromatography-mass spectrometry

MetaboAnalyst 5.0

orthogonal partial least squares discriminant analysis

Variable Importance in Projection

amino acids

personalized therapy

demographic impacts